<DOC>
	<DOCNO>NCT01684098</DOCNO>
	<brief_summary>The folate receptor over-expressed many type cancer cell new folate receptor target therapy develop target cancer cell over-express folate receptor . As targeted therapy , important develop diagnostic test provide accurate information folate receptor status aid select patient may benefit folate-targeted therapy .</brief_summary>
	<brief_title>Safety Efficacy FalateScan ( Technetium Tc 99m EC20 ) Patients With Known Suspected Recurrent Metastatic Cancer From Solid Tumor</brief_title>
	<detailed_description>This Phase II , limited institution , open-label , single-arm , baseline-controlled study design obtain data percentage patient recurrent metastatic cancer solid tumor ( include , limited , breast , lung , mesothelioma , liver , colorectal , prostate , head neck , pancreas , bladder testicular cancer ) increase uptake FalateScan tumor , correlate immunohistochemical staining finding FolateScan image , verify product safety patient suspect recurrent metastatic disease solid tumor .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Technetium Tc 99m-ethylenedicysteine</mesh_term>
	<criteria>Patients must meet follow eligibility requirement enrol study : 1 . Patient must 18 year age old . 2 . Patient must know strongly suspect recurrent metastatic cancer solid tumor least one identifiable lesion &gt; 1.5 cm diagnose conventional imaging . 3 . Patient must adequate kidney function define serum creatinine &lt; 1.5 X ULN . 4 . Patient must adequate liver function define transaminase ( SGOT and/or SGPT ) may 2.5 X ULN alkaline phosphatase &lt; ULN alkaline phosphatase may 2.5 X ULN Transaminases &lt; ULN . If alkaline phosphatase outside parameter due bone metastasis verify assessment isoenzymes , subject eligible . 5 . Patient must provide write informed consent prior enrollment . Patients must exclude follow condition present : 1 . Patient pregnant breastfeeding . 2 . Patient simultaneously participate another investigational drug study , exclude followup phase . 3 . Patient receive investigational agent within 7 day prior enrollment . 4 . Patient unable tolerate condition radionuclide image . 5 . Patient administer another radiopharmaceutical would interfere assessment Technetium Tc 99m EC20 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>recurrent metastatic cancer</keyword>
	<keyword>head neck cancer</keyword>
	<keyword>pancreas cancer</keyword>
	<keyword>bladder cancer</keyword>
	<keyword>testicular cancer</keyword>
</DOC>